Published in Biochim Biophys Acta on February 03, 2010
A Pilot Study of ODSH in Acute Myeloid Leukemia (PGX-AML) | NCT02056782
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol Rev (2011) 2.58
Epithelial stem cells, wound healing and cancer. Nat Rev Cancer (2012) 2.23
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene (2013) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial. Medicine (Baltimore) (2015) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol (2011) 1.41
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol (2013) 1.25
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol (2012) 1.17
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol (2011) 1.12
Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling. Antioxid Redox Signal (2012) 1.11
Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res (2011) 1.11
Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol (2012) 1.09
Autophagy in pancreatic cancer pathogenesis and treatment. Am J Cancer Res (2012) 1.07
Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer (2013) 1.06
The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal (2011) 1.05
The high-mobility group box-1 nuclear factor mediates retinal injury after ischemia reperfusion. Invest Ophthalmol Vis Sci (2011) 1.05
Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol (2015) 1.05
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem (2014) 1.00
MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy (2014) 0.99
A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98
Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc Natl Acad Sci U S A (2011) 0.98
High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med (2012) 0.97
Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One (2012) 0.97
Zinc in innate and adaptive tumor immunity. J Transl Med (2010) 0.95
Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett (2012) 0.95
The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit (2014) 0.95
Intracellular HMGB1 negatively regulates efferocytosis. J Immunol (2011) 0.94
Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol (2010) 0.94
Clinical significance of procoagulant microparticles. J Intensive Care (2015) 0.94
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer (2013) 0.91
High mobility group Box-1 inhibits cancer cell motility and metastasis by suppressing activation of transcription factor CREB and nWASP expression. Oncotarget (2014) 0.90
Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci (2013) 0.90
The Role of receptor for Advanced Glycation End Products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci (2012) 0.90
Autophagy in pancreatic cancer. Int J Cell Biol (2012) 0.90
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem (2015) 0.89
Ménage à Trois in stress: DAMPs, redox and autophagy. Semin Cancer Biol (2013) 0.89
Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis. Mol Cancer (2011) 0.87
Suicidal autointegration of sleeping beauty and piggyBac transposons in eukaryotic cells. PLoS Genet (2014) 0.87
Telomere-regulating genes and the telomere interactome in familial cancers. Mol Cancer Res (2014) 0.87
Context-Dependent Regulation of Autophagy by IKK-NF-κB Signaling: Impact on the Aging Process. Int J Cell Biol (2012) 0.87
The association of HMGB1 gene with the prognosis of HCC. PLoS One (2014) 0.87
Aspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses. Mol Med (2015) 0.87
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87
p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. Mol Cell Proteomics (2015) 0.86
Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending. PLoS One (2013) 0.85
Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem (2013) 0.85
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS One (2015) 0.85
HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes. Front Cell Infect Microbiol (2014) 0.85
HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer (2013) 0.85
Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma. Sci Rep (2015) 0.84
HMGB factors are required for posterior digit development through integrating signaling pathway activities. Dev Dyn (2011) 0.84
High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res (2015) 0.84
Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World J Surg Oncol (2013) 0.84
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm (2013) 0.83
The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review. PLoS One (2014) 0.83
Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells. Chin J Cancer Res (2014) 0.83
Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study. World J Surg Oncol (2015) 0.83
High mobility group box-1 and its clinical value in breast cancer. Onco Targets Ther (2015) 0.83
Gene expression analysis of peripheral blood cells reveals Toll-like receptor pathway deregulation in colorectal cancer. PLoS One (2013) 0.82
Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.81
Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One (2013) 0.81
High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell. Cancer Biol Ther (2012) 0.81
DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev (2014) 0.81
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas (2013) 0.81
Reactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated autophagy. Am J Cancer Res (2015) 0.81
Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci (2011) 0.81
Novel adjuvants from seaweed impede autophagy signaling in therapy-resistant residual pancreatic cancer. J Biomed Sci (2015) 0.81
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med (2016) 0.80
HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget (2016) 0.79
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2. Tumour Biol (2015) 0.79
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol (2015) 0.79
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia (2012) 0.79
High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev (2015) 0.79
Activation of Plant Innate Immunity by Extracellular High Mobility Group Box 3 and Its Inhibition by Salicylic Acid. PLoS Pathog (2016) 0.79
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) (2015) 0.79
Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression. Hepat Mon (2014) 0.78
Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res (2015) 0.78
HMGB1 is a therapeutic target for leukemia. Am J Blood Res (2012) 0.78
Integrating multi-platform genomic data using hierarchical Bayesian relevance vector machines. EURASIP J Bioinform Syst Biol (2013) 0.78
The hallmarks of cancer. Cell (2000) 113.05
Cancer-related inflammation. Nature (2008) 34.21
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature (1990) 7.91
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet (2005) 6.85
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 6.46
Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev (2004) 6.08
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 5.00
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta (1990) 3.55
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol (2001) 3.43
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
p73: Friend or foe in tumorigenesis. Nat Rev Cancer (2002) 3.30
Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med (2006) 3.26
Cancer: Inflaming metastasis. Nature (2009) 3.09
New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J (2001) 3.04
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med (2004) 2.94
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 2.89
Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
HMGB1 loves company. J Leukoc Biol (2009) 2.59
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol (2003) 2.50
High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev (1998) 2.40
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (1999) 2.35
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol (2006) 2.17
Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol (2007) 2.02
Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem (2004) 1.95
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Antioxidants and cancer, part 3: quercetin. Altern Med Rev (2000) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ (2008) 1.84
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol Cell Biol (1997) 1.82
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol (2002) 1.82
Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol (2007) 1.81
Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol (2005) 1.75
The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation (1994) 1.69
High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci U S A (2008) 1.67
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med (2008) 1.62
HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem (2001) 1.60
HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J (2003) 1.59
Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol (2004) 1.57
Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis (2009) 1.56
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med (2009) 1.51
Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol (2007) 1.48
Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem (2007) 1.47
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol (2008) 1.45
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol (2007) 1.43
Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell (2003) 1.43
Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol (2002) 1.43
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate (2005) 1.41
The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol (1977) 1.38
HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol (2009) 1.35
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J Nutr (2005) 1.31
HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol (1999) 1.31
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun (2007) 1.30
HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem (2001) 1.29
Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch (2005) 1.27
Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep (2003) 1.26
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol (2008) 1.21
HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog (2009) 1.20
C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res (2005) 1.19
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis (2008) 1.17
Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol (2003) 1.17
Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin (2007) 1.15
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol (2009) 1.13
Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology (2009) 1.13
Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res (2003) 1.12
KLF4 promotes the expression, translocation, and releas eof HMGB1 in RAW264.7 macrophages in response to LPS. Shock (2008) 1.12
Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther (2009) 1.12
HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun (2003) 1.12
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
HMGB1 promotes drug resistance in osteosarcoma. Cancer Res (2011) 2.82
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol (2006) 2.17
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer (2010) 1.70
UV irradiation resistance-associated gene suppresses apoptosis by interfering with BAX activation. EMBO Rep (2011) 1.68
A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med (2008) 1.62
Arginine and immunity. J Nutr (2007) 1.62
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol (2008) 1.52
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol (2007) 1.48
Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy (2011) 1.47
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol (2007) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett (2004) 1.30
EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc (2010) 1.30
HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy (2010) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol (2013) 1.24
250 robotic pancreatic resections: safety and feasibility. Ann Surg (2013) 1.23
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol (2007) 1.21
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy (2012) 1.19
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12